ABAMETAPIR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H12N2
Molecular Weight	184.2371
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(N=C1)C2=NC=C(C)C=C2

InChI

InChIKey=PTRATZCAGVBFIQ-UHFFFAOYSA-N

InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3

HIDE SMILES / InChI

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/34157881 |https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf

Abametapir is a newly FDA-approved, single-application treatment for head lice in patients aged 6 months and older. Abametapir chelates heavy metal cations and inhibits metalloproteinases critical to louse ova development, hatching, and adult survival. Abametapir lotion, 0.74%, demonstrated significant ovicidal activity against head lice eggs with a single application.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
C-C chemokine receptor type 8 1 Target ID: CHEMBL4596 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22957890	Modulator 846	7943.28 nM [EC50]
C-C chemokine receptor type 1 11 Target ID: CHEMBL2413 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22957890	Modulator 846	17000.0 nM [EC50]
C-C chemokine receptor type 5 20 Target ID: CHEMBL274 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22957890	Modulator 846	2300.0 nM [EC50]
Metalloproteinase 1 Target ID: CHEMBL4495552 Sources: https://pubmed.ncbi.nlm.nih.gov/28082644 \|https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lice infestation 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf	Curative		Approved 8583	XEGLYZE Approved Use Topical treatment of head lice infestation in patients 6 months of age and older Launch Date 2020

C_max

Value	Dose	Analyte	Population
41 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=15 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
72.6 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=15 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
1130 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=16	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR CARBOXYL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2000 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=16	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR CARBOXYL plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
19 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	0.74 mL single, topical dose: 0.74 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	0.74 mL single, topical dose: 0.74 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
169.5 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=46	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
4480.1 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=46	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR CARBOXYL plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
1.79 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=46	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR HYDROXYL plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
120.7 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=15 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
263.9 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=15 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
4900 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=16	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR CARBOXYL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11400 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=16	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR CARBOXYL plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
59 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	0.74 mL single, topical dose: 0.74 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
154.2 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	0.74 mL single, topical dose: 0.74 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
461.7 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=46	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
28241.5 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=46	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR CARBOXYL plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN
6.76 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=46	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:	ABAMETAPIR HYDROXYL plasma	Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
21.3 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=15 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	1.48 mL single, topical dose: 1.48 mL route of administration: Topical experiment type: SINGLE co-administered:		ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28.8 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=41	0.74 mL single, topical dose: 0.74 mL route of administration: Topical experiment type: SINGLE co-administered:		ABAMETAPIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
7.7% OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000PharmR.pdf#page=26			ABAMETAPIR plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2.5% OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000PharmR.pdf#page=26			ABAMETAPIR CARBOXYL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.74 % single, topical Highest studied dose Dose: 0.74 % Route: topical Route: single Dose: 0.74 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf	Other AEs: No toxicities were reported... Other AEs: No toxicities were reported Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf
0.74 % single, topical MTD Dose: 0.74 % Route: topical Route: single Dose: 0.74 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf	Other AEs: No toxicities were reported... Other AEs: No toxicities were reported Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf
0.74 % single, topical Studied dose Dose: 0.74 % Route: topical Route: single Dose: 0.74 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000SumR.pdf	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000SumR.pdf	Other AEs: No toxicities were reported... Other AEs: No toxicities were reported Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000SumR.pdf

AEs

AE	Dose	Population
No toxicities were reported	0.74 % single, topical Highest studied dose Dose: 0.74 % Route: topical Route: single Dose: 0.74 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf
No toxicities were reported	0.74 % single, topical MTD Dose: 0.74 % Route: topical Route: single Dose: 0.74 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000MedR.pdf
No toxicities were reported	0.74 % single, topical Studied dose Dose: 0.74 % Route: topical Route: single Dose: 0.74 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000SumR.pdf	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000SumR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 110 OAT3 747 OCT2 779 CYP3A5 136 P-gp 1741 CYP2C19 2057 CYP1A2 2153 CYP2C8 1057 CYP2B6 926 OATP1B1 1079 OATP1B3 961 BCRP 910 OAT1 725	CYP 303 CYP2B6 776 CYP1A2 1197 P-gp 2052 UGT 219 OATP1B3 435 OAT3 391 OATP1B1 503 OAT1 395 OCT2 434 BCRP 697	CYP2B6 669 CYP1A2 832

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf#page=4 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 8 \| 20 \| 21	minor [Ki 39 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf#page=4 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 8 \| 20 \| 21	no [IC50 >40 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 20 \| 21	no [IC50 >40 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 20 \| 21	no [IC50 >40 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 20 \| 21	no [IC50 >40 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 20 \| 21	no [IC50 >40 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf#page=4 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 8 \| 20 \| 21	no [IC50 >40 uM]
CYP3A5 201	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 20 \| 21	no [IC50 >40 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=28 Page: 28 \| 29	no	Abametapir carboxyl 1
CYP 150	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 Page: 8.0	no	Abametapir carboxyl 1
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=22 Page: 22 \| 23	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=23 Page: 23 \| 24	no	Abametapir carboxyl 1
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=22 Page: 22 \| 23	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=23 Page: 23 \| 24	no	Abametapir carboxyl 1
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=22 Page: 22 \| 23	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=23 Page: 23 \| 24	no	Abametapir carboxyl 1
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=26 Page: 26 \| 27	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=26 Page: 26 \| 27	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=26 Page: 26 \| 27	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=28 Page: 28 \| 29	no	Abametapir carboxyl 1
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=26 Page: 26 \| 27	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
CYP3A5 201	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=19 Page: 19 \| 21 \| 22	unlikely	Abametapir carboxyl 1
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=26 Page: 26 \| 27	weak [Inhibition 120 uM]
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=28 Page: 8 \| 25 \| 28 \| 29	yes [IC50 17.1 uM]	Abametapir carboxyl 1
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25 \| 26 \| 27	yes [IC50 35.4 uM]
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25 \| 26 \| 27	yes [IC50 57.5 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=28 Page: 8 \| 25 \| 28 \| 29	yes [IC50 >100 uM]	Abametapir carboxyl 1
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25 \| 28 \| 29	yes [IC50 >100 uM]	Abametapir carboxyl 1
CYP 150	supressor 160 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=20 Page: 20.0	yes	Abametapir carboxyl 1
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=28 Page: 8 \| 25 \| 28 \| 29	yes	Abametapir carboxyl 1
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=28 Page: 8 \| 25 \| 28 \| 29	yes	Abametapir carboxyl 1

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 Page: 8 \| 17	major
CYP2B6 776	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 Page: 8 \| 17	minor
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=24 Page: 8 \| 24	no
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25	no	Abametapir carboxyl 1
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 Page: 8 \| 18	no	Abametapir carboxyl 1
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=24 Page: 8 \| 24 \| 25	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25	no	Abametapir carboxyl 1
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=24 Page: 8 \| 24 \| 25	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25	no	Abametapir carboxyl 1
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=24 Page: 8 \| 24 \| 25	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25	no	Abametapir carboxyl 1
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=24 Page: 8 \| 24 \| 25	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25	no	Abametapir carboxyl 1
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=24 Page: 8 \| 24 \| 25	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25	no	Abametapir carboxyl 1
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=24 Page: 8 \| 24	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=25 Page: 8 \| 25	no	Abametapir carboxyl 1
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 Page: 8 \| 17	yes	Abametapir carboxyl 1
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000ClinPharmR.pdf#page=8 Page: 8 \| 17	yes	Abametapir hydroxyl 1

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000PharmR.pdf#page=29 Page: 29.0

PubMed

Title	Date	PubMed
Intramolecular metal...sulfur interactions of platinum(II) 1,4,7-trithiacyclononane complexes with bipyridyl ligands: the relationship between molecular and electronic structures.	2005 Mar 21	15762722
Di-μ(1,1)-azido-bis-[azido-(5,5'-dimethyl-2,2'-bipyridine)nickel(II)].	2008 Nov 20	21581175
Trichlorido(5,5'-dimethyl-2,2'-bipyridine-κN,N')(methanol-κO)indium(III).	2008 Oct 4	21580816
Dichlorido(6-methyl-2,2'-bipyridine-κN,N')zinc(II).	2008 Sep 13	21201019
Bis[dichlorido(5,5'-dimethyl-2,2'-bi-pyridine-κN,N')gold(III)] tetra-chlorido-aurate(III) dichloridooaurate(I).	2009 Feb 28	21582104
Dichloridobis(phenanthridine-κN)zinc(II).	2009 Jun 6	21582680
Aqua-bis(benzoato-κO)(5,5'-dimethyl-2,2'-bipyridine-κN,N')copper(II).	2009 Oct 3	21578058
catena-Poly[[(5,5'-dimethyl-2,2'-bi-pyridine-κN,N')cadmium(II)]-di-μ-iodido].	2010 Apr 24	21579044
catena-Poly[[aqua-(5,5'-dimethyl-2,2'-bipyridine-κN,N')copper(II)]-μ-2,2'-oxydibenzoato-κO:O'].	2010 Jul 10	21588146
Tri-μ-sulfato-κO:O'-bis-[aqua-(1,10-phenanthroline-κN,N')indium(III)] dihydrate.	2010 Sep 15	21587408

Patents

Sample Use Guides

In Vivo Use Guide

Apply XEGLYZE to dry hair in an amount sufficient (up to the full content of one bottle) to thoroughly coat the hair and scalp. Avoid contact with eyes. Massage XEGLYZE into the scalp and throughout the hair; leave on the hair and scalp for 10 minutes and then rinse off with warm water. Treatment with XEGLYZE involves a single application.

Route of Administration: Topical

In Vitro Use Guide

In the in vitro pharmacology screen, 10 uM abametapir inhibited the activity of cyclooxygenase-1 by 52.3% and activity of MMP-9 by 24.4%.

Name

Type

Language

abametapir [INN]

Preferred Name

English

ABAMETAPIR

Official Name

English

ABAMETAPIR [USAN]

Common Name

English

ABAMETAPIR [MI]

Common Name

English

XEGLYZE

Brand Name

English

ABAMETAPIR [ORANGE BOOK]

Common Name

English

HA-44

Code

English

6,6'-BI-3-PICOLINE

Common Name

English

5,5'-DIMETHYL-2,2'-DIPYRIDYL

Common Name

English

HA44

Code

English

2,2'-BIPYRIDINE, 5,5'-DIMETHYL-

Systematic Name

English

Abametapir [WHO-DD]

Common Name

English

5,5'-DIMETHYL-2,2'-BIPYRIDINE

Systematic Name

English

Code System Code Type Description

PUBCHEM

15664